BAM
KZR

Belpointe Asset Management’s Kezar Life Sciences KZR Stock Holding History

Belpointe Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9
Closed -$275 – 2098
2023
Q1 		$275 Hold
9
– – ﹤0.01% 3648
2022
Q4 		$620 Buy
+9
New +$667 ﹤0.01% 3516

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Belpointe Asset Management's KZR Position: Q2 2023 in Review

Belpointe Asset Management sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 9 shares — an estimated $275 sold.

Belpointe Asset Management first reported a position in KZR in Q4 2022 and held it in 2 quarters. The position peaked at $620 in Q4 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Belpointe Asset Management reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 9 Kezar Life Sciences shares in Q2 2023, an estimated $275.
  • Belpointe Asset Management first reported a position in Kezar Life Sciences in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Kezar Life Sciences position peaked at $620 in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.